Usted buscó: hypercholesterolemia (Inglés - Lituano)

hypercholesterolemia
hipercholeste- rolemija

anorexia hypercholesterolemia hypertriglyceridaemia
anoreksija hipercholesterolemija hipertrigliceridemija

fluid retention, hypercholesterolemia
nerimas, nemiga,

hypercholesterolemia, weight gain, hyperglycemia, hunger
sutrikimai hipercholesterinemija, svorio padidjimas, hiperglikemija, alkio pojtis.

tumour lysis syndrome, dehydration, hypoalbuminemia, hypercholesterolemia
naviko irimo sindromas, dehidratacija, hipoalbuminemija, hipercholesterolemija.

leucopoenia bleeding time prolonged hypercholesterolemia hypertriglyceridaemia ataxia confusion
hipercholesterolemija hipertrigliceridemija ataksija sumisimas miastenija parestezija anoreksija astenija galvos svaigimas mieguistumas

hypercholesterolemia still is an indication, but mainly in combination with such dyslipidaemia.
hipercholesterolemija tebepriskiriama prie indikacij, taciau dazniausiai tuomet, jei pacientas serga dar ir dislipidemija.

the dosage of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily.
homozigotine seimine hipercholesterolemija sergantiems ligoniams atorvastatino paros doz yra 10 ­ 80 mg.

-to reduce total-c and ldl-c in patients with homozygous familial hypercholesterolemia an
-norint sumazinti bendro cholesterolio ir ldl-cholesterolio koncentracij, kai pacientai serga

diarrhoea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridaemia and hypercholesterolemia may occur later.
viduriavimas, pykinimas ir vėmimas gali pasireikšti gydymo pradžioje, o hipertrigliceridemija ir hipercholesterolemija vėliau.

the most common adverse reactions related to kaletra therapy during clinical trials were diarrhoea, nausea, vomiting, hypertriglyceridaemia and hypercholesterolemia.
klinikinių tyrimų metu dažniausia su kaletra susijusi nepageidaujama reakcija buvo viduriavimas, vėmimas, hipertriglicerolemija ir hipercholesterolemija.

rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol) sulfasalazine for inflammatory bowel disease or rheumatoid arthritis
rozuvastatino, simvastatino, atorvastatino, pravastatino (vaistų nuo hipercholesterolemijos, t. y. didelio cholesterolio kiekio); sulfasalazino (vaisto nuo uždegimu pasireiškiančios žarnyno ligos ar reumatoidinio artrito);

in patients with a known risk factor for cardiovascular disease, monitoring of the blood lipid levels is recommended, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine.
jei pacientai turi sirdies ir kraujagysli ligos rizikos faktori, rekomenduojama stebti lipid kiek kraujyje, nes vartojantiems gliukozamin ligoniams buvo nustatyti keli hipercholesterolemijos atvejai.

experience in pediatrics is limited to a small number of patients (age 4 -17 years) with severe dyslipidemias, such as homozygous familial hypercholesterolemia.
vaik gydymo patirtis yra maza:{ sugalvotas } gydyta tik nedaug 4 -17 met pacient, serganci sunkia dislipidemija, pvz., homozigotine seimine hipercholesterolemija.

the statins are now the primary choice in patients with hypercholesterolemia due to the superior low-density lipoproteins (ldl)-cholesterol lowering properties and the demonstrated benefit in outcome.
statinai siuo metu yra tinkamiausi vaistai pacientams, sergantiems hipercholesterolemija, vis pirma dl j savybs mazinti mazo tankio lipoprotein (ldl) kiek ir dl ger rezultat.

b, and tryglicerides in patients with primary hypercholesterolemia including familial hypercholesterolemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
apolipoproteino b ir triglicerid koncentracij, kai pacientams bdinga hipercholesterinemija, skaitant paveldim hipercholesterinemij (hibridinis variantas) , arba sudtin (misri) hiperlipidinemija (atitinkanti fredrickson klasifikacijos iia ir iib tipus) ir kai reakcija diet ir kitas nefarmakologines priemones yra nepakankama;